OM
Omeros Corporation
OMER · NASDAQ
$17.34 +0.93% (+$0.16)
1M -0.12%
Market Cap $1.35B
P/E Ratio 10.78x
Div. Yield -
ROE -
Bulios Fair Price
$11.29
34.9% downside
Current Price
$17.34
Undervalued Fair Value Overvalued
According to Bulios Fair Price, OMER is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
69 /100
Cheap P/E 10.78x
EV/EBITDA 10.48x
P/S 35.02x
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
40 /100
Moderate Gross margin 95.77%
Net margin 324.88%
Op. margin 189.53%
Quality
24 /100
Poor ROIC 31.14%
ROA 43.52%
Asset turnover 0.13x
Debt
87 /100
Low Current ratio 1.95x
Int. coverage 5.95x
Net debt/EBITDA 0.60x
Stability
1 /100
Unstable Beta 2.60x
EPS volatility 317.41%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about OMER
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Gregory A. Demopulos
Employees
175
Headquarters
Seattle
Upcoming events
12 NOV
Earnings
Upcoming earnings report